Apellis (APLS) stock slides 15% after $689 mln 2025 revenue preview at JPM conference
New York, Jan 12, 2026, 14:41 EST — Regular session Apellis Pharmaceuticals shares dropped almost 15% Monday following the release of preliminary 2025 U.S. sales numbers ahead of its J.P. Morgan Healthcare Conference update. The move put the stock in